FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010322784> ?p ?o ?g. }

• W3010322784 endingPage "2205" @default.
• W3010322784 startingPage "2193" @default.
• W3010322784 abstract "Background There have been concerns regarding increased peritransplantation complications, especially severe acute graft‐versus‐host disease (aGVHD), in patients with prior use of checkpoint inhibitors (CPI) before hematopoietic stem cell transplantation (HSCT). Methods The authors performed a retrospective study of 43 patients with acute myeloid leukemia and/or myelodysplastic syndromes who were treated with an antiprogrammed cell death protein 1 (PD‐1) (32 patients) or anticytotoxic T‐lymphocyte–associated protein 4 (CTLA‐4) (9 patients) blockade or both (2 patients) prior to HSCT with the primary outcome of aGVHD by day 100 after HSCT. Outcome analyses were stratified by GVHD prophylaxis as use of post‐HSCT cyclophosphamide (PTCy) (22 patients) or not (non‐PTCy) (21 patients). Results The PTCy group demonstrated a trend toward lower grade 3 to 4 aGVHD when compared with the non‐PTCy group (5% vs 22%), although the rates of grade 2 to 4 aGVHD were comparable (49% vs 56%). The interval between CPI and HSCT did not appear to impact the incidence of aGVHD. However, a higher incidence of grade 3 to 4 aGVHD was observed in patients who received >4 treatments of CPI prior to HSCT if they were not given PTCy as GVHD prophylaxis (43% vs 12%). Matched control analyses using patients with no prior use of CPI confirmed the increase in grade 3 to 4 aGVHD with those agents. However, that increased risk was limited to patients who did not receive PTCy and was not observed in patients who received PTCy as GVHD prophylaxis. Despite persistent improvement in GVHD with the use of PTCy, disease control was not compromised and progression‐free survival at 1 year was found to be superior for patients treated with PTCy compared with those not receiving PTCy among patients with prior use of CPI (55% vs 22%). Conclusions The results of the current study indicated that HSCT with prior use of CPI appears feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of PTCy as GVHD prophylaxis improves outcomes." @default.
• W3010322784 created "2020-03-13" @default.
• W3010322784 creator A5000750846 @default.
• W3010322784 creator A5020340537 @default.
• W3010322784 creator A5022647201 @default.
• W3010322784 creator A5026334708 @default.
• W3010322784 creator A5029855695 @default.
• W3010322784 creator A5034104852 @default.
• W3010322784 creator A5035605515 @default.
• W3010322784 creator A5035622739 @default.
• W3010322784 creator A5036412023 @default.
• W3010322784 creator A5047522685 @default.
• W3010322784 creator A5048913229 @default.
• W3010322784 creator A5049385583 @default.
• W3010322784 creator A5055885795 @default.
• W3010322784 creator A5061026876 @default.
• W3010322784 creator A5066894053 @default.
• W3010322784 creator A5069176297 @default.
• W3010322784 creator A5071033599 @default.
• W3010322784 creator A5085076031 @default.
• W3010322784 creator A5090435894 @default.
• W3010322784 creator A5091083304 @default.
• W3010322784 date "2020-03-03" @default.
• W3010322784 modified "2023-10-15" @default.
• W3010322784 title "Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors" @default.
• W3010322784 cites W187238933 @default.
• W3010322784 cites W1893566975 @default.
• W3010322784 cites W1899957715 @default.
• W3010322784 cites W2039334806 @default.
• W3010322784 cites W2071523891 @default.
• W3010322784 cites W2125616358 @default.
• W3010322784 cites W2126724696 @default.
• W3010322784 cites W2128812336 @default.
• W3010322784 cites W2132289468 @default.
• W3010322784 cites W2140875987 @default.
• W3010322784 cites W2148233118 @default.
• W3010322784 cites W2152591595 @default.
• W3010322784 cites W2155464214 @default.
• W3010322784 cites W2307073326 @default.
• W3010322784 cites W2412214702 @default.
• W3010322784 cites W2412725897 @default.
• W3010322784 cites W2465734185 @default.
• W3010322784 cites W2473498748 @default.
• W3010322784 cites W2490433371 @default.
• W3010322784 cites W2559537906 @default.
• W3010322784 cites W2567998110 @default.
• W3010322784 cites W2594496276 @default.
• W3010322784 cites W2610269487 @default.
• W3010322784 cites W2611189127 @default.
• W3010322784 cites W2612422239 @default.
• W3010322784 cites W2733520933 @default.
• W3010322784 cites W2745549673 @default.
• W3010322784 cites W2792398247 @default.
• W3010322784 cites W2890693336 @default.
• W3010322784 cites W2890700249 @default.
• W3010322784 cites W2900410545 @default.
• W3010322784 cites W4239140112 @default.
• W3010322784 doi "https://doi.org/10.1002/cncr.32796" @default.
• W3010322784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32125707" @default.
• W3010322784 hasPublicationYear "2020" @default.
• W3010322784 type Work @default.
• W3010322784 sameAs 3010322784 @default.
• W3010322784 citedByCount "30" @default.
• W3010322784 countsByYear W30103227842020 @default.
• W3010322784 countsByYear W30103227842021 @default.
• W3010322784 countsByYear W30103227842022 @default.
• W3010322784 countsByYear W30103227842023 @default.
• W3010322784 crossrefType "journal-article" @default.
• W3010322784 hasAuthorship W3010322784A5000750846 @default.
• W3010322784 hasAuthorship W3010322784A5020340537 @default.
• W3010322784 hasAuthorship W3010322784A5022647201 @default.
• W3010322784 hasAuthorship W3010322784A5026334708 @default.
• W3010322784 hasAuthorship W3010322784A5029855695 @default.
• W3010322784 hasAuthorship W3010322784A5034104852 @default.
• W3010322784 hasAuthorship W3010322784A5035605515 @default.
• W3010322784 hasAuthorship W3010322784A5035622739 @default.
• W3010322784 hasAuthorship W3010322784A5036412023 @default.
• W3010322784 hasAuthorship W3010322784A5047522685 @default.
• W3010322784 hasAuthorship W3010322784A5048913229 @default.
• W3010322784 hasAuthorship W3010322784A5049385583 @default.
• W3010322784 hasAuthorship W3010322784A5055885795 @default.
• W3010322784 hasAuthorship W3010322784A5061026876 @default.
• W3010322784 hasAuthorship W3010322784A5066894053 @default.
• W3010322784 hasAuthorship W3010322784A5069176297 @default.
• W3010322784 hasAuthorship W3010322784A5071033599 @default.
• W3010322784 hasAuthorship W3010322784A5085076031 @default.
• W3010322784 hasAuthorship W3010322784A5090435894 @default.
• W3010322784 hasAuthorship W3010322784A5091083304 @default.
• W3010322784 hasBestOaLocation W30103227841 @default.
• W3010322784 hasConcept C120665830 @default.
• W3010322784 hasConcept C121332964 @default.
• W3010322784 hasConcept C126322002 @default.
• W3010322784 hasConcept C143998085 @default.
• W3010322784 hasConcept C167135981 @default.
• W3010322784 hasConcept C2776694085 @default.
• W3010322784 hasConcept C2776755627 @default.
• W3010322784 hasConcept C2777408962 @default.
• W3010322784 hasConcept C2779972918 @default.

• next